UROV Urovant Sciences Ltd.

11.67
+1.03  (+10%)
Previous Close 10.64
Open 10.86
Price To Book -77.8
Market Cap 356,167,875
Shares 30,519,955
Volume 207,123
Short Ratio
Av. Daily Volume 66,421
Stock charts supplied by TradingView

NewsSee all news

  1. Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access

    Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years' experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston

  2. Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference

    Urovant Sciences (NASDAQ:UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies

  3. Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting

    52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control Urovant Sciences (NASDAQ:UROV) announced today that

  4. Urovant Sciences Ltd. General Corporate Statement (Form8) (0001193125-20-099584)

  5. Urovant Sciences Appoints James Robinson as President and Chief Executive Officer

    Mr. Robinson will assume the role of President and CEO and continue as a Urovant Board Member Mr. Robinson's deep experience in the urology and overactive bladder markets makes him ideally suited to succeed Keith

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a top-line data due 2H 2020.
Vibegron
Irritable bowel syndrome (IBS)
Phase 3 top-line data due 2021
Vibegron - COURAGE
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
PDUFA date December 26, 2020.
Vibegron
Overactive bladder (OAB)
Phase 2a cohort 1 enrolment to be completed 2H 2020.
URO-902
Overactive bladder (OAB)

Latest News

  1. Urovant Sciences Appoints Walt Johnston as Senior Vice President of Commercial, Kenton Stewart as Senior Vice President of Market Access

    Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years' experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston

  2. Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference

    Urovant Sciences (NASDAQ:UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies

  3. Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting

    52-Week Post Hoc Analysis Shows Vibegron Patients Had Statistically Significant, Sustained Reduction in UUI and Total Incontinence Episodes Compared to Active Control Urovant Sciences (NASDAQ:UROV) announced today that

  4. Urovant Sciences Ltd. General Corporate Statement (Form8) (0001193125-20-099584)

  5. Urovant Sciences Appoints James Robinson as President and Chief Executive Officer

    Mr. Robinson will assume the role of President and CEO and continue as a Urovant Board Member Mr. Robinson's deep experience in the urology and overactive bladder markets makes him ideally suited to succeed Keith

  6. Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder

    Urovant Sciences (NASDAQ:UROV) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for once-daily 75 mg vibegron for the treatment of

  7. Urovant Sciences Announces Publication of Phase 3 EMPOWUR Trial Results in the Journal of Urology

    Urovant Sciences (NASDAQ:UROV) announced today the publication of the efficacy and safety results of vibegron in patients with overactive bladder (OAB) from the international Phase 3 EMPOWUR trial. The peer-reviewed

  8. Urovant Sciences to Present at Cowen and Company's 40th Annual Health Care Conference

    Urovant Sciences (NASDAQ:UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 5:40 a.m. Pacific / 8:40 a.m. Eastern on Tuesday, March 3, 2020, at Cowen and Company's 40th Annual

  9. Hercules Capital Reports Fourth Quarter and Record Full-Year 2019 Financial Results

    Company Achieves Multiple Records for FY 2019: Total New Debt and Equity Commitments, Total Gross Fundings, Total Investment Income, Net Investment Income, Total Investment Assets and Total Debt Investments among

  10. Urovant Sciences Reports 2019 Third Fiscal Quarter Financial Results

    Urovant Sciences (NASDAQ:UROV) today reported financial results for the 2019 third fiscal quarter ended December 31, 2019. Recent Business Highlights Submitted a New Drug Application for vibegron for the treatment

  11. Urovant Sciences to Report 2019 Third Fiscal Quarter Financial Results

    Urovant Sciences (NASDAQ:UROV) announced today that it will report 2019 third fiscal quarter financial results after the close of U.S. financial markets on Thursday, February 13, 2020. Management will host a

  12. Urovant Sciences Announces Publication of Results from Phase 1 Clinical Trials Evaluating URO-902 Gene Therapy in Patients with Overactive Bladder

    Urovant Sciences (NASDAQ:UROV) announced today the publication of the safety and efficacy results of URO-902 in female patients with overactive bladder (OAB) from two double-blind, placebo-controlled randomized Phase 1

  13. Urovant Sciences to Ring the Nasdaq Stock Market Opening Bell

    Urovant Sciences (NASDAQ:UROV) announced today that Chief Executive Officer Keith Katkin and other Urovant executives will ring the opening bell of the Nasdaq Stock Market on Tuesday, January 21, 2020, at 9:30 a.m.

  14. Urovant Sciences to Present at the 38th Annual J.P. Morgan Healthcare Conference

    Urovant Sciences (NASDAQ:UROV) announced today that Chief Executive Officer Keith Katkin will give a presentation at 4:30 p.m. Pacific / 7:30 p.m. Eastern on Wednesday, January 15, 2020, at the 38th Annual J.P. Morgan

  15. Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder

    Urovant Sciences (NASDAQ:UROV) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of once-daily 75mg vibegron for the treatment of patients

  16. Urovant Sciences Enters into $300 Million Term Loan Agreement with Sumitomo Dainippon Pharma

    Urovant Sciences (NASDAQ:UROV) ("Urovant") announced today that it has entered into a $300 million term loan facility with Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) ("Sumitomo Dainippon Pharma"), a leading global

  17. Urovant Sciences Majority Shareholder, Roivant Sciences, and Sumitomo Dainippon Pharma Complete Transaction for Strategic Alliance

    Urovant Sciences (NASDAQ:UROV) ("Urovant") announced today that its majority shareholder, Roivant Sciences Ltd. ("Roivant"), and Sumitomo Dainippon Pharma Co., Ltd. (TSE: 4506) ("Sumitomo Dainippon Pharma"), a leading

  18. Urovant Sciences Initiates Patient Enrollment in Phase 2a Study of URO-902

    Urovant Sciences (NASDAQ:UROV), announced today that the first patient has been enrolled in a Phase 2a study evaluating the efficacy and safety of URO-902, a novel gene therapy product, in patients with overactive

  19. Urovant Sciences Reports 2019 Second Fiscal Quarter Financial Results

    Urovant Sciences (NASDAQ:UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the 2019 second

  20. Urovant Sciences Secures Substantial Financial Commitment, Commercial Infrastructure Support and Minority Shareholder Protections from Sumitomo Dainippon Pharma Upon Close of Sumitomo Dainippon Pharma's Transaction with Roivant Sciences

    Sumitomo Dainippon Pharma has committed to provide an initial $200 million, low-interest, interest-only, five-year term loan facility, with no repayments due until the end of the term Sumitomo Dainippon Pharma

  21. Urovant Sciences Reports Positive Long-Term Data from the Double-Blind Extension of the Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder

    Vibegron further improved treatment benefit on key overactive bladder (OAB) symptoms over the 40-week extension period 41% of patients on vibegron became "dry," defined as having no urge urinary incontinence episodes

  22. Urovant Sciences Parent Company, Roivant Sciences, and Sumitomo Dainippon Pharma Enter into a Memorandum of Understanding to Create Broad Strategic Alliance

    Sumitomo Dainippon Pharma is expected to fully assume Roivant's ownership interest of Urovant Sciences (approximately 75% of outstanding Urovant shares); definitive agreement expected by the end of October